Abstract:Background: Chemotherapy is currently one of the most common/important treatments for cancers; however the occurrence of multidrug resistance (MDR) impedes the successful application of chemotherapeutic agents. The active efflux of anti-cancer drugs through multi-drug resistance protein 1 (MRP1) remains the dominant mechanism of MDR. However, mechanisms underlying the MRP1 upregulation during tumorigenesis and chemotherapy remain elusive. Methods: MRP1 expression, the efflux probability and viability were measured to evaluate MDR of human lung cancer A549/DDP and H1299 cells. Pharmacological treatment, shRNA-based konckdown and rescue were used to assess the function of JNK (c-Jun N-terminal kinase) and Sp1 (stimulatory phosphatase 1). Chromatin immunoprecipitation and dual-luciferase reporter assay were used to test the direct binding and activation of MRP1 promotor by Sp1. Findings: Pharmacological analysis and JNK knockdown revealed the direct modulation of MRP1 expression and MDR by by the JNK signaling pathway. Furthermore, the transcript factor Sp1 downstream of JNK showed close association with MRP1 expression and MDR. Chromatin immunoprecipitation and luciferase assays revealed the direct binding and activation of MRP1 promoter by Sp1, while Sp1 knockdown decreased MRP1 expression and reversed MDR. Importantly, the MRP1 upregulation and MDR mediated by JNK activation were substantially abolished by Sp1 knockdown in both A549/DDP and H1299 cells. Interpretation: This work demonstrates that Sp1 is a critical transcription factor for MRP1 downstream of JNK and plays a key role in MRP1 upregulation and MDR during tumorigenesis and chemotherapy. Targeting Sp1 expression/activation sheds new light on the clinical chemotherapy treatments of cancers.Funding Statement: This work was supported by the National Natural Science Foundation of China (31400708 and 31670843), the Natural Science Foundation of Heilongjiang Province, China (C200624, C201241, and C201453), the Shaanxi Natural Science Funds for Distinguished Young Scholars of China (2019JC-07), the Key Research and Development Program of Shaanxi Province, China (2017SF-113), and the Fundamental Research Funds for the Central Universities (2017qngz10).Declaration of Interests: The authors declare no competing financial interests.Ethics Approval Statement: Not required.

Role of post-translational modifications of Sp1 in cancer: state of the art

Research Progress on Relationship Between Transcription Factor Sp1 and Tumor

Role of post-translational modifications of Sp1 in cardiovascular diseases

Sp1 and the ‘hallmarks of cancer’

SP1 Mediates MRP1 Upregulation and Multi-Drug Resistance in Human Lung Cancer Cells

Crosstalk of Sp1 and Stat3 Signaling in Pancreatic Cancer Pathogenesis

The role of histone post-translational modifications in cancer and cancer immunity: functions, mechanisms and therapeutic implications

Post-translational modification of SOX family proteins: Key biochemical targets in cancer?

Pan-cancer analysis of Sp1 with a focus on immunomodulatory roles in gastric cancer

Significant Biological Role of Sp1 Transactivation in Multiple Myeloma

Secreted Phosphoprotein 1 As a Potential Prognostic and Immunotherapy Biomarker in Multiple Human Cancers

Protein post-translational modifications in the regulation of cancer hallmarks

Emerging Role of Protein Post-Translational Modification in the Potential Clinical Application of Cancer

The role of protein post-translational modifications in prostate cancer

Regulation and Role of Post-Translational Modifications of Enhancer of Zeste Homologue 2 in Cancer Development.

Transcription Factor Specifidty Protein 1: a New Biomarker for Pancreatic Cancer Therapy

Regulating tumor suppressor genes: post-translational modifications

A pan-cancer analysis of the oncogenic role of secreted phosphoprotein 1 (SPP1) in human cancers

SP1 Expression and the Clinicopathological Features of Tumors: A Meta-Analysis and Bioinformatics Analysis.

The roles of post-translational modifications and coactivators of STAT6 signaling in tumor growth and progression

Research progression in post-translational protein modification sumoylation in cancer